Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.

Pauline Wils (1, 2) , Philippe Seksik (1, 2) , Carmen Stefanescu (1, 2) , Stephane Nancey (1, 2) , Matthieu Allez (1, 2) , Guillaume Pineton de Chambrun (1, 2, 3) , Romain Altwegg (1, 2) , Cyrielle Gilletta (1, 2) , Lucine Vuitton (1, 2) , Stéphanie Viennot (1, 2) , Mélanie Serrero (1, 2) , Mathurin Fumery (1, 2) , Guillaume Savoye (4, 5, 6, 7) , Michael Collins (1, 2) , Felix Goutorbe (1, 2) , Hedia Brixi (1, 2) , Guillaume Bouguen (1, 2) , Noémie Tavernier (1, 2) , Medina Boualit (1, 2) , Aurélien Amiot (1, 2) , Vered Abitbol (1, 2) , David Laharie (1, 2) , Benjamin Pariente (1, 2)

1 GETAID - Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif
2 PREGNANCY-GETAID - Grossesse - Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif
3 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
4 ADEN - Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau
5 IRIB - Institute for Research and Innovation in Biomedicine
6 Service d'Hépato-Gastroentérologie [CHU Rouen]
7 UNIROUEN UFR Santé - UNIROUEN - UFR Santé

The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD.

Domains: Hépatology and Gastroenterology

Pauline Wils, Philippe Seksik, Carmen Stefanescu, Stephane Nancey, Matthieu Allez, et al.. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.. Alimentary Pharmacology & Therapeutics (Suppl), 2020, ⟨10.1111/apt.16192⟩. ⟨hal-03138226⟩